mr1-1
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT01009866)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin A
Oral
No
Parenteral
No
Topical
No
Also known as
- mr1-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01009866 | Phase 1 | Nov 1, 2006 | Duke University, National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1